FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alain Rolland

Research Profile

Chemicals & Drugs

Living Beings

Procedures

Disorders

Co-author Network

Publications

TOP 3
Jukka Hartikka; Jane Morrow; Alain Rolland; Denis Rusalov; Mark Shlapobersky; Sean Sullivan; Qun Wei; Mary K Wloch; Ming Ye; Sou Boutsaboualoy; Vesselina Bozoukova; John Doukas; Larry R Smith
Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.
John Doukas; Thomas Hilgert; Doug Jones; Rohit Mahajan; Terrie Martin; Jane Morrow; Denis Rusalov; Sean Sullivan; Dawn Bellinger; Alain Rolland
Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.
Larry R Smith; Mary K Wloch; Ming Ye; Luane R Reyes; Souphaphone Boutsaboualoy; Casey E Dunne; Jennifer A Chaplin; Denis Rusalov; Alain Rolland; Cindy L Fisher; Mohamed S Al-Ibrahim; Martin L Kabongo; Roy Steigbigel; Robert B Belshe; Ernest R Kitt; Alice H Chu; Ronald B Moss
Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alain Rolland (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Jukka Hartikka; Jane Morrow; Alain Rolland; Denis Rusalov; Mark Shlapobersky; Sean Sullivan; Qun Wei; Mary K Wloch; Ming Ye; Sou Boutsaboualoy; Vesselina Bozoukova; John Doukas; Larry R Smith
Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.
Human vaccines & immunotherapeutics 2012;8(11):1595-606.
2011: John Doukas; Thomas Hilgert; Doug Jones; Rohit Mahajan; Terrie Martin; Jane Morrow; Denis Rusalov; Sean Sullivan; Dawn Bellinger; Alain Rolland
Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.
Vaccine 2011;29(33):5443-52.
2010: Larry R Smith; Mary K Wloch; Ming Ye; Luane R Reyes; Souphaphone Boutsaboualoy; Casey E Dunne; Jennifer A Chaplin; Denis Rusalov; Alain Rolland; Cindy L Fisher; Mohamed S Al-Ibrahim; Martin L Kabongo; Roy Steigbigel; Robert B Belshe; Ernest R Kitt; Alice H Chu; Ronald B Moss
Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
Vaccine 2010;28(13):2565-72.
2009: Jukka Hartikka; Vesselina Bozoukova; Catherine K Yang; Ming Ye; Denis Rusalov; Mark Shlapobersky; Adrian Vilalta; Qun Wei; Alain Rolland; Larry R Smith
Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.
Vaccine 2009;27(46):6399-403.
2007: Gretchen S Jimenez; Rodrick Planchon; Qun Wei; Denis Rusalov; Andrew Geall; Joel Enas; Peggy Lalor; Vicky Leamy; Ruth Vahle; Catherine J Luke; Alain Rolland; David C Kaslow; Larry R Smith
Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.
Human vaccines 2007;3(5):157-64.
2007: Adrian Vilalta; Gretchen S Jimenez; Denis Rusalov; Rodrick Planchon; Peggy Lalor; Kristin Carner; Jennifer A Chaplin; Michael Komai; Marston Manthorpe; David C Kaslow; Alain Rolland
Vaccination with polymerase chain reaction-generated linear expression cassettes protects mice against lethal influenza A challenge.
Human gene therapy 2007;18(8):763-71.
2006: Vicky Leamy; Terrie Martin; Rohit Mahajan; Adrian Vilalta; Denis Rusalov; Jukka Hartikka; Vesselina Bozoukova; Keith D Hall; Jane Morrow; Alain Rolland; David C Kaslow; Peggy Lalor
Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines.
Human vaccines 2006;2(3):113-8.
2005: Adrian Vilalta; Rohit K Mahajan; Jukka Hartikka; Vicky Leamy; Terrie Martin; Denis Rusalov; Vesselina Bozoukova; Peggy Lalor; Keith Hall; David C Kaslow; Alain Rolland
II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential.
Human gene therapy 2005;16(10):1151-6.
2005: Adrian Vilalta; Rohit K Mahajan; Jukka Hartikka; Denis Rusalov; Terrie Martin; Vesselina Bozoukova; Vicky Leamy; Keith Hall; Peggy Lalor; Alain Rolland; David C Kaslow
I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration.
Human gene therapy 2005;16(10):1143-50.
2005: Marston Manthorpe; Peter Hobart; Gary Hermanson; Marilyn Ferrari; Andrew Geall; Blake Goff; Alain Rolland
Plasmid vaccines and therapeutics: from design to applications.
Advances in biochemical engineering/biotechnology 2005;99():41-92.
2004: Marilyn E Ferrari; Gary Hermanson; Alain Rolland
Development of anthrax DNA vaccines.
Current opinion in molecular therapeutics 2004;6(5):506-12.